MX2020004863A - Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. - Google Patents
Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro.Info
- Publication number
- MX2020004863A MX2020004863A MX2020004863A MX2020004863A MX2020004863A MX 2020004863 A MX2020004863 A MX 2020004863A MX 2020004863 A MX2020004863 A MX 2020004863A MX 2020004863 A MX2020004863 A MX 2020004863A MX 2020004863 A MX2020004863 A MX 2020004863A
- Authority
- MX
- Mexico
- Prior art keywords
- defense
- premature
- defensins
- glp
- mucosa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201002 | 2017-11-10 | ||
| PCT/EP2018/080814 WO2019092201A2 (en) | 2017-11-10 | 2018-11-09 | Maturation of mucosal defense and gut/lung function in the preterm infant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004863A true MX2020004863A (es) | 2020-10-14 |
Family
ID=60301879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004863A MX2020004863A (es) | 2017-11-10 | 2018-11-09 | Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200316172A1 (https=) |
| EP (1) | EP3706773A2 (https=) |
| JP (1) | JP2021502363A (https=) |
| KR (1) | KR20200095472A (https=) |
| CN (1) | CN111556759A (https=) |
| AU (1) | AU2018363783A1 (https=) |
| BR (1) | BR112020009254A2 (https=) |
| CA (1) | CA3082288A1 (https=) |
| MX (1) | MX2020004863A (https=) |
| RU (1) | RU2020115758A (https=) |
| SG (1) | SG11202003868UA (https=) |
| WO (1) | WO2019092201A2 (https=) |
| ZA (1) | ZA202002992B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019006848A (es) * | 2016-12-13 | 2019-10-07 | Defensin Therapeutics Aps | Metodos para tratar condiciones inflamatorias de los pulmones. |
| PL3713590T3 (pl) * | 2017-11-24 | 2025-09-15 | Defensin Therapeutics Aps | Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi |
| KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| CN114903973B (zh) * | 2022-04-21 | 2025-08-29 | 上海市肺科医院 | 一种呼吸道粘膜免疫增强药物组合物 |
| US20240252558A1 (en) * | 2023-01-29 | 2024-08-01 | The University Of Chicago | Probiotics to rescue maternal immune activation-induced neurodevelopment deficits |
| KR20240150943A (ko) | 2023-04-10 | 2024-10-17 | (주)인트젠 | 영유아용 유산균 프로바이오틱스 조성물 |
| CN116868958A (zh) * | 2023-09-06 | 2023-10-13 | 中国人民解放军军事科学院军事医学研究院 | 构建缺氧导致肠道应激损伤的动物模型的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| CA2502324A1 (en) * | 2002-10-14 | 2004-04-29 | Lars Thim | Glucagon - like peptide - 2 variants |
| JP2007063219A (ja) * | 2005-09-01 | 2007-03-15 | Juntendo | 新生児壊死性腸炎疾患予防剤 |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| SG172709A1 (en) * | 2008-07-18 | 2011-07-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins |
| US20110223137A1 (en) * | 2008-12-05 | 2011-09-15 | Nestec S.A. | Compositions for use in low-birth weight infants |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| JP6219277B2 (ja) * | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| EA201200416A1 (ru) * | 2012-03-12 | 2013-09-30 | Аделя Сабир кызы Гаджиева | Способ ранней диагностики и лечения некротического энтероколита у новорожденных |
| SG11201406628RA (en) * | 2012-04-23 | 2014-11-27 | Chiesi Farma Spa | Method and system for the administration of a pulmonary surfactant by atomization |
| EP2968073B1 (en) * | 2013-03-13 | 2017-08-16 | Rush University Medical Center | Delivery device for oropharyngeal administration of mother's colostrum and milk |
| BR112018015170A2 (pt) * | 2016-01-26 | 2018-12-18 | Defensin Therapeutics Aps | métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1. |
| MX2019006848A (es) * | 2016-12-13 | 2019-10-07 | Defensin Therapeutics Aps | Metodos para tratar condiciones inflamatorias de los pulmones. |
-
2018
- 2018-11-09 MX MX2020004863A patent/MX2020004863A/es unknown
- 2018-11-09 JP JP2020524879A patent/JP2021502363A/ja active Pending
- 2018-11-09 AU AU2018363783A patent/AU2018363783A1/en not_active Abandoned
- 2018-11-09 CA CA3082288A patent/CA3082288A1/en active Pending
- 2018-11-09 SG SG11202003868UA patent/SG11202003868UA/en unknown
- 2018-11-09 RU RU2020115758A patent/RU2020115758A/ru unknown
- 2018-11-09 EP EP18800163.0A patent/EP3706773A2/en active Pending
- 2018-11-09 KR KR1020207015411A patent/KR20200095472A/ko not_active Ceased
- 2018-11-09 BR BR112020009254-1A patent/BR112020009254A2/pt not_active IP Right Cessation
- 2018-11-09 CN CN201880085608.5A patent/CN111556759A/zh active Pending
- 2018-11-09 US US16/761,980 patent/US20200316172A1/en active Pending
- 2018-11-09 WO PCT/EP2018/080814 patent/WO2019092201A2/en not_active Ceased
-
2020
- 2020-05-21 ZA ZA2020/02992A patent/ZA202002992B/en unknown
-
2024
- 2024-06-17 US US18/745,301 patent/US20250009844A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111556759A (zh) | 2020-08-18 |
| BR112020009254A2 (pt) | 2020-10-27 |
| JP2021502363A (ja) | 2021-01-28 |
| KR20200095472A (ko) | 2020-08-10 |
| US20250009844A1 (en) | 2025-01-09 |
| WO2019092201A3 (en) | 2019-06-27 |
| ZA202002992B (en) | 2021-10-27 |
| RU2020115758A (ru) | 2021-12-10 |
| CA3082288A1 (en) | 2019-05-16 |
| SG11202003868UA (en) | 2020-05-28 |
| US20200316172A1 (en) | 2020-10-08 |
| EP3706773A2 (en) | 2020-09-16 |
| WO2019092201A2 (en) | 2019-05-16 |
| AU2018363783A1 (en) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004863A (es) | Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. | |
| Kwon et al. | Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells | |
| Burnham et al. | Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance | |
| Vazquez-Ortiz et al. | Life-threatening anaphylaxis to egg and milk oral immunotherapy in asthmatic teenagers | |
| Herman et al. | Pulmonary surfactant as a versatile biomaterial to fight COVID-19 | |
| MX394965B (es) | Interfaz respiratoria. | |
| Castagnola et al. | Role of G-CSF GM-CSF in the management of infections in preterm newborns: an update | |
| MX353649B (es) | Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos. | |
| ES2555557R1 (es) | Fármaco y uso para preparar un medicamento destinado a la prevención de la infección del VIH y al tratamiento de enfermedades causadas por el VIH, incluido el SIDA | |
| Manzoni et al. | Recent advances in prevention of sepsis in the premature neonates in NICU | |
| MX2019006831A (es) | Vacuna oral contra enfermedades respiratorias de ruminantes que contiene polivinilpirrolidona. | |
| ECSP18000069A (es) | Sistemas de administración oral para agentes bioactivos | |
| Robichaud et al. | Role of probiotics in prevention of COVID-19 through modulation of gut–lung axis | |
| MY206419A (en) | Hepatitis b vaccine transnasal administration system | |
| Drysdale et al. | Intussusception risk after rotavirus vaccination in England | |
| Marerrambeĭli et al. | Comparative evaluation of effectiveness of the combined immunocorrection in patients suffering severe craniocerebral trauma | |
| Misra et al. | pathogens MDPI | |
| Palshina et al. | THE INFLUENCE OF URINARY TRACT INFECTIONS ON TREATMENT OF FRACTURE OF PROXIMAL FEMUR IN PATIENTS WITH SYSTEMIV OSTEOPOROSIS | |
| Cavalcante | Development of daptomycin-methicillin-resistant staphylococcus aureus: case report | |
| Costill | PHiD-CV10 vaccine slightly reduces use of tubes for ear infections | |
| Han et al. | C94 HIGH IMPACT CLINICAL TRIALS IN CRITICAL CARE: A Pilot Randomized Controlled Trial Of High-Dose Vitamin D In Lung Failure | |
| NIRMALA et al. | OVERVIEW OF COVID-19 AS GLOBAL PANDEMIC | |
| Stewart et al. | C43 CRITICAL CARE: NEW CARE APPROACHES: Severe Alcohol Withdrawal Syndrome Managed With Expectant Rather Than Preemptive Endotracheal Intubation | |
| Rady et al. | The Canadian guidelines for the withdrawal of life-sustaining treatment: the role of evidence | |
| KIM et al. | The use of rituximab with immune tolerance induction therapy for hemophilia A with inhibitors |